Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus PK in Diabetic Kidney-Pancreas Transplant Recipients
NCT04496401Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in transplant rejection, sponsored by CHU de Nantes. Primary endpoint: Bioavailability of Envarsus compared to tacrolimus. Started Sep 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
transplant rejection
Beyond the preview
Go deeper on NCT04496401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496401.